Earli is addressing the #1 problem in cancer: What is cancer, and what is not? In its quest, Earli has gone from a 13% detection rate of real patient lung cancer samples with the initial construct to now 98% detection on the same samples, by building entirely new synthetic constructs. The next step is to force cancer cells to produce cytokines that activate the immune system against themselves.
“When you work with the Black Diamond Ventures team, you are among entrepreneurs. They are entrepreneurs themselves, who are constantly advancing and iterating as they learn. That is how you build companies that change the world.” ~ Cyriac Roeding, CEO